daunorubicin has been researched along with topotecan in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kaufmann, SH | 1 |
| Adjei, A; Burke, PJ; Cheng, YC; Donehower, RC; Gore, SD; Grochow, LB; Jones, RJ; Kaufmann, SH; Rowinsky, EK | 1 |
| Leslie, KK | 1 |
| Estey, EH; Thall, PF | 1 |
| Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D | 1 |
| Centurioni, R; Corvatta, L; Leoni, F; Leoni, P; Malerba, L; Marconi, M; Masia, MC; Mele, A; Offidani, M; Scortechini, A | 1 |
| Karp, J | 1 |
| Bennett, JM; Cripe, LD; Dewald, GW; Gore, SD; Lazarus, HM; Lee, SJ; Litzow, MR; Othus, M; Paietta, EM; Rowe, JM; Tallman, MS | 1 |
| Chan, GC; Law, HK; Li, J; Liu, YL | 1 |
| Castellon, EA; Castillo, V; Contreras, HR; Huidobro, C; Valenzuela, R | 1 |
| de Jong, J; Neefjes, J; Pang, B; Qiao, X; Wessels, LF | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
1 review(s) available for daunorubicin and topotecan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for daunorubicin and topotecan
| Article | Year |
|---|---|
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Camptothecin; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia; Male; Middle Aged; Mouth Mucosa; Quinidine; Remission Induction; Stomatitis; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Bone Marrow Diseases; Burkitt Lymphoma; Comorbidity; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Carriers; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, T-Cell; Life Tables; Liposomes; Male; Methotrexate; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Safety; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Gemtuzumab; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Topotecan | 2010 |
13 other study(ies) available for daunorubicin and topotecan
| Article | Year |
|---|---|
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1991 |
Chemotherapy and pregnancy.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Fetus; Humans; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Topotecan; Trastuzumab; Vinblastine; Vincristine | 2002 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
[Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells].
Topics: Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Cisplatin; Daunorubicin; Humans; Hydroxyurea; Inhibitory Concentration 50; Mesenchymal Stem Cells; Topotecan | 2010 |
Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Neoplasm Proteins; Neoplastic Stem Cells; Prostatic Neoplasms; Spheroids, Cellular; Topotecan; Tumor Cells, Cultured | 2014 |
Chemical profiling of the genome with anti-cancer drugs defines target specificities.
Topics: Aclarubicin; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genome, Human; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Transport; Structure-Activity Relationship; Topoisomerase Inhibitors; Topotecan | 2015 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |